JP2013501807A - インフルエンザの治療および診断のための組成物および方法 - Google Patents

インフルエンザの治療および診断のための組成物および方法 Download PDF

Info

Publication number
JP2013501807A
JP2013501807A JP2012524878A JP2012524878A JP2013501807A JP 2013501807 A JP2013501807 A JP 2013501807A JP 2012524878 A JP2012524878 A JP 2012524878A JP 2012524878 A JP2012524878 A JP 2012524878A JP 2013501807 A JP2013501807 A JP 2013501807A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antibodies
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012524878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501807A5 (enExample
Inventor
アンドレス ジー. ザ サード グランデア,
ゴードン キング,
トーマス シー. コックス,
オーレ オルセン,
ジェニファー ミッチャム,
マシュー モイル,
フィル ハモンド,
Original Assignee
セラクローン サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラクローン サイエンシーズ, インコーポレイテッド filed Critical セラクローン サイエンシーズ, インコーポレイテッド
Publication of JP2013501807A publication Critical patent/JP2013501807A/ja
Publication of JP2013501807A5 publication Critical patent/JP2013501807A5/ja
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012524878A 2009-08-14 2010-08-12 インフルエンザの治療および診断のための組成物および方法 Pending JP2013501807A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23415409P 2009-08-14 2009-08-14
US61/234,154 2009-08-14
PCT/US2010/045346 WO2011019932A2 (en) 2009-08-14 2010-08-12 Compositions and methods for the therapy and diagnosis of influenza

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015030186A Division JP2015120738A (ja) 2009-08-14 2015-02-19 インフルエンザの治療および診断のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2013501807A true JP2013501807A (ja) 2013-01-17
JP2013501807A5 JP2013501807A5 (enExample) 2013-09-19

Family

ID=43586846

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012524878A Pending JP2013501807A (ja) 2009-08-14 2010-08-12 インフルエンザの治療および診断のための組成物および方法
JP2015030186A Pending JP2015120738A (ja) 2009-08-14 2015-02-19 インフルエンザの治療および診断のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015030186A Pending JP2015120738A (ja) 2009-08-14 2015-02-19 インフルエンザの治療および診断のための組成物および方法

Country Status (7)

Country Link
US (1) US8974788B2 (enExample)
EP (1) EP2464383A4 (enExample)
JP (2) JP2013501807A (enExample)
AU (1) AU2010282415A1 (enExample)
CA (1) CA2771105A1 (enExample)
TW (1) TW201117825A (enExample)
WO (1) WO2011019932A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395784T3 (es) * 2007-11-12 2013-02-15 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnosis de la influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2675478A4 (en) * 2011-02-14 2015-06-10 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
KR20140012131A (ko) * 2011-03-15 2014-01-29 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2988781A4 (en) * 2013-04-22 2017-04-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP3076993A1 (en) * 2013-12-05 2016-10-12 Janssen Vaccines & Prevention B.V. Process for preparing influenza vaccines
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US20180179265A1 (en) * 2015-04-27 2018-06-28 The Trustees Of The University Of Pennsylvania Engineered human anti-aav antibodies and uses thereof
KR20220047277A (ko) * 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
TWI867224B (zh) * 2020-06-08 2024-12-21 中央研究院 重組抗體或片段,以及其用途
WO2022132710A1 (en) * 2020-12-15 2022-06-23 Vanderbilt University Human hendra virus and nipah virus antibodies and methods of use therefor
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009064805A1 (en) * 2007-11-12 2009-05-22 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183797A (en) * 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
US8080244B2 (en) * 2008-11-21 2011-12-20 Los Alamos National Security, Llc Anti-influenza M2e antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009064805A1 (en) * 2007-11-12 2009-05-22 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of influenza

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014035440; WANG, R. et al.: 'Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein' ANTIVIRAL RESEARCH Vol.80, No.2, 2008, p.168-177 *

Also Published As

Publication number Publication date
CA2771105A1 (en) 2011-02-17
WO2011019932A2 (en) 2011-02-17
WO2011019932A9 (en) 2011-06-16
US8974788B2 (en) 2015-03-10
TW201117825A (en) 2011-06-01
JP2015120738A (ja) 2015-07-02
US20110070235A1 (en) 2011-03-24
EP2464383A4 (en) 2013-02-13
AU2010282415A1 (en) 2012-03-08
WO2011019932A3 (en) 2011-08-18
EP2464383A2 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
JP5623332B2 (ja) インフルエンザの治療および診断のための組成物および方法
US8900590B2 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
JP2016519688A (ja) インフルエンザの治療および診断のための組成物および方法
JP2015120738A (ja) インフルエンザの治療および診断のための組成物および方法
JP2014506580A (ja) インフルエンザの治療および診断のための組成物および方法
US8858948B2 (en) Compositions and methods for the therapy and diagnosis of influenza
US20130158238A1 (en) Compositions and Methods for the Therapy and Diagnosis of Influenza
JP2014509591A (ja) インフルエンザの治療および診断のための組成物および方法
TWI473621B (zh) 供治療和診斷流感用之組成物和方法
HK1195741A (en) Compositions and methods for the therapy and diagnosis of influenza
HK1147767B (en) Compositions and methods for the therapy and diagnosis of influenza
AU2013206604A1 (en) Compositions and Methods for the Therapy and Diagnosis of Influenza

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150814